Enfortumab vedotin
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Small Bowel Adenocarcinoma
Conditions
Advanced Small Bowel Adenocarcinoma
Trial Timeline
Nov 4, 2025 → Sep 30, 2028
NCT ID
NCT07347314About Enfortumab vedotin
Enfortumab vedotin is a phase 2 stage product being developed by Astellas Pharma for Advanced Small Bowel Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07347314. Target conditions include Advanced Small Bowel Adenocarcinoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Small Bowel Adenocarcinoma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07139977 | Phase 2 | Recruiting |
| NCT07347314 | Phase 2 | Recruiting |
| NCT06862219 | Approved | Recruiting |
| NCT06891560 | Phase 2 | Recruiting |
| NCT06553885 | Phase 2 | Recruiting |
| NCT06394570 | Phase 1/2 | Recruiting |
| NCT06011954 | Pre-clinical | Recruiting |
| NCT05868265 | Phase 2 | Recruiting |
| NCT04754191 | Phase 2 | Active |
| NCT05014139 | Phase 1 | Terminated |
| NCT04995419 | Phase 2 | Completed |
| NCT03219333 | Phase 2 | Completed |
| NCT03070990 | Phase 1 | Completed |
| NCT02091999 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Small Bowel Adenocarcinoma